Rosell, R. (Rafael)

Filtering

2018 - 20192

Settings

Author search.filters.isAuthorOfPublication.771e36b5-84e0-4ac6-9009-324f454c04b0

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
    (Future Medicine Ltd, 2019) Linke, R. (Rolf); Pluzanski, A. (Adam); Wu, Y.L. (Yi-Long); Mok, T.S. (Tony S.); Nakagawa, K. (Kazuhiko); Corral-Jaime, J. (Jesús); Migliorino, M.R. (Maria Rita); Tan, W. (Weiwei); Devgan, G. (Geeta); Quinn, S. (Susan); Wang, T. (Tao); Rosell, R. (Rafael); Lee, K.H. (Ki Hyeong)
    Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement.
  • Thumbnail Image
    Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    (SAGE Publications, 2018) Rodríguez-Abreu, D. (Delvys); Gonzalez-Cao, M. (María); Perez-Ruiz, E. (Elisabeth); Martin-Algarra, S. (Salvador); Llanos-Gil, M. (Maria) de los; Marquez-Rodas, I. (Iván); Royo, M.A. (María Ángeles); Teixidó, C. (Cristina); Puertolas, T. (Teresa); Drozdowskyj, A. (Ana); Rosell, R. (Rafael); Gimenez-Capitan, A. (Ana); Blanco, R. (Remedios); Karachaliou, N. (Niki); Viteri, S. (S.); Crespo, G. (Guillermo); Aldeguer, E. (Erika); Molina-Vila, M.A. (Miguel Angel)
    Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.